Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459930 | 0.85 | HSD17B10 (0.33) | HSD17B10RAB9A | |
| SCHEMBL2459425 | 0.85 | PDK1 (0.39) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL15909553 | 0.79 | PDK1 (0.59) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL5560259 | 0.79 | PDK1 (0.59) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL509358 | 0.79 | PDK1 (0.59) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL16797367 | 0.77 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL17791708 | 0.77 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL17893278 | 0.77 | PDK1 (0.42) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL19056428 | 0.77 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL19056488 | 0.77 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | PDK1 4023/4885PDK2 2659/4885PDK3 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.